Evidence map›Paper›PMID 31262748›Full record

ArticleDisease models & mechanisms2019

Insulin receptor substrate 2 (IRS2) deficiency delays liver fibrosis associated with cholestatic injury.

Andrea Villar-Lorenzo, Patricia Rada, Esther Rey, Patricia Marañón, Ana I Arroba, Beatriz Santamaría, Jorge Sáiz, Francisco J Rupérez, Coral Barbas, Carmelo García-Monzón and 2 more

Open access · goldAbstract read
In one paragraph

Article in Disease models & mechanisms, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. What lies beyond 100 years of insulin.Disease models & mechanisms · 2021
    Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Andrea Villar-LorenzoInstituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), 28029 Madrid, Spain.
Patricia RadaInstituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), 28029 Madrid, Spain.
Esther ReyUnidad de Investigación Hepática, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, 28009 Madrid, Spain.
Patricia MarañónUnidad de Investigación Hepática, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, 28009 Madrid, Spain.ORCID 0000-0002-6229-6287
Ana I ArrobaInstituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), 28029 Madrid, Spain.
Beatriz SantamaríaInstituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), 28029 Madrid, Spain.
Jorge SáizCentre for Metabolomics and Bioanalysis (CEMBIO), Faculty of Pharmacy, Universidad San Pablo CEU, Campus Monteprincipe, Boadilla del Monte, 28668, Madrid, Spain.
Francisco J RupérezCentre for Metabolomics and Bioanalysis (CEMBIO), Faculty of Pharmacy, Universidad San Pablo CEU, Campus Monteprincipe, Boadilla del Monte, 28668, Madrid, Spain.
Coral BarbasCentre for Metabolomics and Bioanalysis (CEMBIO), Faculty of Pharmacy, Universidad San Pablo CEU, Campus Monteprincipe, Boadilla del Monte, 28668, Madrid, Spain.
Carmelo García-MonzónUnidad de Investigación Hepática, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, 28009 Madrid, Spain.
Ángela M ValverdeInstituto de Investigaciones Biomédicas Alberto Sols (CSIC-UAM), 28029 Madrid, Spain avalverde@iib.uam.es aguedagr.phd@gmail.com.
Águeda González-RodríguezUnidad de Investigación Hepática, Hospital Universitario Santa Cristina, Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa, 28009 Madrid, Spain avalverde@iib.uam.es aguedagr.phd@gmail.com.ORCID 0000-0003-2851-2318
Instituto de Salud Carlos III · ESUniversidad San Pablo CEU · ESHospital Universitario Santa Cristina · ESInstituto de Investigaciones Biomédicas Sols-Morreale · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Insulin receptor substrate 2 (IRS2) is a key downstream mediator of insulin and insulin-like growth factor 1 (IGF1) signalling pathways and plays a major role in liver metabolism. The aim of this study was to investigate whether IRS2 had an impact on the hepatic fibrotic process associated with cholestatic injury. Bile duct ligation (BDL) was performed in wild-type (WT) and

Indexed as

AnimalsBile DuctsCell LineCholestasisFemaleHepatic Stellate CellsHumansInsulin-Like Growth Factor IInsulin Receptor Substrate ProteinsLiver CirrhosisMiceMice, KnockoutSignal Transductioninsulin-like growth factor-1, mouseInsulin-Like Growth Factor IInsulin Receptor Substrate ProteinsIrs2 protein, mouseBile acidsCholestatic injuryFibrosisHepatic stellate cellsIGF1IRS2

Identifiers

PMID31262748
PMCPMC6679376
OpenAlexW2954735229

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.